PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PAN subgroup compared with 7 days (moderate certainty).
PPI triple therapy for 14 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PCN subgroup compared with 7 days (very low certainty).
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes eradication rate compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
The intervention showed no clear difference in eradication proportion (moderate certainty).
PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
PPI triple therapy for 14 days probably leads to higher patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes gastrointestinal adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes allergic adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
The intervention showed no clear difference in geographic region (low certainty).
The intervention showed no clear difference in publication date (moderate certainty).
The intervention showed no clear difference in STT length (high certainty).
It is very uncertain whether the intervention changes bacterial antibiotic resistance (very low certainty).
The intervention showed no clear difference in adverse events rate (high certainty).